Patents Examined by Samantha L Shterengarts
  • Patent number: 10441624
    Abstract: An application of dipeptide as an ACE enzyme activity inhibitor. Virtual screening is performed on 400 types of dipeptide based on ACE inhibiting effects thereof according to a detected ACE enzyme crystal structure by using self-developed software and adopting a molecular docking method, experiments are conducted to verify the ACE inhibitory activity of the dipeptide obtained by virtual screening, and it finds out that the dipeptide with the N terminal as cysteine has better ACE inhibitory activity.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: October 15, 2019
    Assignee: WITHYOU BIOTECHNOLOGY CO., LTD.
    Inventors: Xionglei He, Wei Zhu
  • Patent number: 10428083
    Abstract: The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: October 1, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Michael Härter, Dirk Kosemund, Martina Delbeck, Bernd Kalthof, Pierre Wasnaire, Frank Süβmeier, Klemens Lustig
  • Patent number: 10426788
    Abstract: Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: October 1, 2019
    Assignee: Unity Biotechnology, Inc.
    Inventor: Nathaniel David
  • Patent number: 10428022
    Abstract: Formula IA, and their use for treating viral infections.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: October 1, 2019
    Assignee: Emergent Virology LLC
    Inventors: Urban Ramstedt, Kelly Lyn Warfield, Anthony Treston
  • Patent number: 10428021
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: October 1, 2019
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • Patent number: 10420718
    Abstract: The present invention relates to effervescent compositions which are resistant to water vapor in the atmosphere and to methods of preparing such compositions. In particular, the invention relates to an effervescent composition comprising a co-crystal. The co-crystal comprises an acidic component and a basic component is separate. The co-crystal comprising the acidic component is resistant to water uptake avoiding initiating the effervescence prematurely. Upon dissolution of the co-crystal and the basic component effervescence occurs.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: September 24, 2019
    Assignee: University of Bradford
    Inventors: Anant Paradkar, Sudhir Pagire
  • Patent number: 10420781
    Abstract: A thyroid hormone receptor agonist and its use in the treatment of a disease associated thyroid hormone receptor beta are described. The compound can be effective in lowering cholesterol with minimum or no adverse effects on the heart or thyroid hormone axis.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: September 24, 2019
    Assignee: Metabasis Therapeutics Inc.
    Inventors: Mark Erion, Hongjian Jiang, Serge Henri Boyer
  • Patent number: 10413557
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 17, 2019
    Assignee: FORENDO PHARMA LTD.
    Inventors: Leena Hirvelä, Pasi Koskimies, Risto Lammintausta, Marjo Hakola, Maire Eloranta
  • Patent number: 10407382
    Abstract: Described herein are compounds that are EP4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP4 receptors.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: September 10, 2019
    Assignee: ALLERGAN, INC.
    Inventors: David W. Old, Christopher D. Hein
  • Patent number: 10407399
    Abstract: The presently-disclosed subject matter relates to analyte-activated photolabile compounds. The compounds include the formula: wherein Z includes a maskable molecule; L is selected from a bond, C, C(O), O, alkyl, (O)alkyl, and alkoxy; R1 is selected from H, halogen, alkyl, and acyl; each R2 is independently selected from H, alkyl, aryl, and acyl, and is optionally substituted with one or more heteroatoms independently selected from COOH and COO(alkyl); and R3 is selected from H, alkyl, aryl, halogen, CN, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, CHO, COOH, COO(alkyl), COO(aryl), PO3H2, and SO3H, and is optionally substituted with one or more heteroatoms independently selected from N, O, and S, halogen, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, NO2, CHO, COO, COOH, COO(alkyl), COO(aryl), C(O)NR2, PO3H2, and/or SO3H. Also provided are methods of detecting calcium and treating a subject with the analyte-activated photolabile compounds.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: September 10, 2019
    Assignee: HOWARD HUGHES MEDICAL INSTITUTE
    Inventors: Luke D. Lavis, Jonathan B. Grimm, Laurel M. Heckman, Eric R. Schreiter
  • Patent number: 10399948
    Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 3 (mGlu3), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, cognitive disorders, schizophrenia, Alzheimer's disease, or cancer in a subject.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: September 3, 2019
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Julie L. Engers, Katrina A. Bollinger, Megan M. Breiner
  • Patent number: 10385069
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for use in the treatment of cancer, an inflammatory disorder, an autoimmunity disorder or a neurodegenerative disorder.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: August 20, 2019
    Assignee: Active Biotech AB
    Inventors: Ulf Wellmar, Stephen East, Marie Bainbridge, Colin MacKinnon, James Carr, Jonathan Hargrave
  • Patent number: 10377786
    Abstract: A green route for preparing a metal organic framework include mixing metal precursor with a ligand precursor to form a solvent-free mixture; adding droplets of water to the mixture; heating the mixture at a first temperature after adding the water; and isolating the metal organic framework material including the metal and the ligand.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: August 13, 2019
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Mohamed Eddaoudi, Osama Shekhah, Youssef Belmabkhout
  • Patent number: 10377780
    Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: August 13, 2019
    Assignees: The Governing Council of the University of Toronto, UTI Limited Partnership, Indiana University Research and Technology Corporation
    Inventors: Patrick Thomas Gunning, Sina Haftchenary, Brent David George Page, Samuel Weiss, Hema Artee Luchman, Melissa L. Fishel
  • Patent number: 10369122
    Abstract: The present invention relates to compounds, compositions, lipid-like nanoparticles, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a polynucleotide).
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: August 6, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Yizhou Dong, Bin Li
  • Patent number: 10370388
    Abstract: The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: August 6, 2019
    Assignee: NOVARTIS AG
    Inventors: Thomas David McCarthy, Alan Naylor
  • Patent number: 10364238
    Abstract: The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: July 30, 2019
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • Patent number: 10358436
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 23, 2019
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
  • Patent number: 10336728
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: July 2, 2019
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Qun Li
  • Patent number: 10322107
    Abstract: Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: June 18, 2019
    Assignee: Nektar Therapeutics
    Inventors: Franco J. Duarte, Neel K. Anand, Wen Zhang, Pankaj Sharma, Devendrapratap Singh